Recent

% | $
Quotes you view appear here for quick access.

CARBO Ceramics Inc. Message Board

momentum74 8 posts  |  Last Activity: May 25, 2016 11:50 AM Member since: Feb 28, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    DNAI 6.05 prior completed studies bullish.

    by momentum74 May 25, 2016 11:46 AM
    momentum74 momentum74 May 25, 2016 11:50 AM Flag

    11 patients achieving a complete response (CR), partial response (PR) or stable disease (SD). Furthermore, all four of the diffuse large B-cell lymphoma (DLBCL) patients treated in this trial experienced a clinical response, including three CRs and one PR, with reported durations on study in the range of nine to more than 20 months.

    For more information, please go to Clinicaltrials bullish

    Sentiment: Strong Buy

  • Go to pronai site for more info.

    Completed studies

    We have conducted two clinical trials with single-agent PNT2258 to date: a Phase 1 safety trial in 22 patients with relapsed or refractory solid tumors and a Phase 2 trial in 13 patients with relapsed or refractory NHL.

    Phase 1 dose escalation clinical trial

    We initiated our Phase 1 dose escalation clinical trial with PNT2258 in 2010 to determine the safety and tolerability of PNT2258 administered by intravenous infusion. This Phase 1 trial involved 22 patients with relapsed or refractory solid tumor malignancies, including patients diagnosed with non-small cell lung cancer, squamous cell cancer of the head and neck, colorectal cancer, breast cancer, endometrial cancer, liver cancer, pancreatic cancer and prostate cancer. As this trial was safety oriented, patients were not chosen for participation on the basis of their BCL2 status and, thus, overt evidence of anti-tumor effect was not expected. PNT2

    258 was considered to be well tolerated at all doses by the investigators in this trial. In addition, there was no evidence of a systemic immune response to the LNP or PNT100; no significant changes in immune-stimulatory cytokines or clinical signs of anap8hylaxis following dosing of PNT2258 were observed, which supports the lack of a non-specific immune response.

    For more information, please go to Clinicaltrials.gov.

    Phase 2 trial in relapsed or refractory NHL

    In December 2012, we initiated a single arm, open-label Phase 2 trial in patients with relapsed or refractory NHL, defined as patients who are no longer or were never responsive to treatment with approved or experimental therapies. The primary objective was to determine PNT2258’s anti-tumor activity across several hematological malignancies and to collect safety data.

    In this trial, which enrolled 13 patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), PNT2258 demonstrated evidence of anti-tumor activity, with 11

    Sentiment: Strong Buy

  • Hopefully they are continuing to buy this quarter as well. Volume has been strong for about a week now. Long for a swing bounce trade. source whalewisdom

    Sentiment: Strong Buy

  • Sheff is one of the best biotech traders around. Volume is starting to surge.

    Pasted.
    New Economy Portfolio Update..Entered that has a big Oral presentation at ASCO 16 on June 6th. 52wk low is $4.48 & 52wk high is $33.75. Lots of upside here.

    Alert..entered $DNAI at $5.26 (10%) in the New Economy Portfolio. 300K shares have traded with 45m left in the trading day. This should continue to move higher into & thru ASCO.

    Sentiment: Strong Buy

  • VANCOUVER, May 18, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (DNAI), a clinical-stage oncology company advancing novel targeted therapeutics for patients with cancer, today announced it will present interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) on June 6th at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).

    Sentiment: Strong Buy

  • Looks like the move into the June results could be starting. There is also an annual shareholders meeting coming in June. The average daily volume is starting to increase. Best of luck to all traders and investors. Long at 5.32 for swing bounce-trade.

    Sentiment: Strong Buy

  • Stock trading near cash was down 11 days in a row until today. Very oversold technically , looking for a nice rally. My average price is 5.32 .

    Sentiment: Strong Buy

  • 5 Stocks Poised for Big Breakouts
    By Roberto Pedone Follow | 03/04/16 - 07:14 AM EST
    ProNAi Therapeutics

    A clinical-stage oncology player that's starting to spike within range of triggering a big breakout trade is ProNAi Therapeutics (DNAI) , which develops and commercializes a class of therapeutics based on its DNA interference technology platform for patients with cancer and hematological diseases. This stock has been annihilated by the bears over the last six months, with shares dropping sharply lower by 79.5%.

    If you take a glance at the chart for ProNAi Therapeutics, you'll notice that this stock recently formed a double bottom chart pattern, after shares found some buying interest at $5.85 to $5.70 a share. Following that potential bottom, shares of ProNAi Therapeutics have now started to spike sharply higher, and it's quickly trending within range of triggering a big breakout trade above some near-term overhead resistance levels.

    Traders should now look for long-biased trade in ProNAi Therapeutics if it manages to break out above its 20-day moving average of $6.57 a share and then above more key resistance levels at $6.62 to around $7 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 143,485 shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.46 to $8.60, or even $9 to its 50-day moving average of $9.53 a share.

    Traders can look to buy ProNAi Therapeutics off weakness to anticipate that breakout and simply use a stop that sits right around its new 52-week low of $5.70 a share. One could also buy this stock off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point. (end of article)

    I have been loading this stock for the last two. Avg cost is 6.59 now.

    Sentiment: Strong Buy

CRR
12.09-0.32(-2.58%)May 26 4:02 PMEDT